

# Genentech

*A Member of the Roche Group*

## **Notice Regarding Recalculated 340B Ceiling Prices for Genentech Product Avastin - 4 ml (100 mg) impacted for the time period 3Q 2014 through 4Q 2014**

Genentech, Inc. ("Genentech") has recalculated Average Manufacturer Price ("AMP") values previously submitted to the Centers for Medicare & Medicaid Services ("CMS") for Avastin - 4ml (100mg) from 10 2014 through 20 2014. Genentech has also recalculated the 340B ceiling prices for the affected product and associated quarters of 30 2014 through 40 2014 based on the corrected AMP values.

Genentech has asked the Office of Pharmacy Affairs ("OPA") to post this notice on OPA's public website to ensure transparency by providing access to information regarding Genentech's recalculation and refund program to the public and specifically, to any affected 340B Covered Entity.

Genentech will issue refunds to 340B Covered Entities where our data indicates a difference between the original and recalculated 340B ceiling price for direct and indirect purchases in favor of Covered Entities of those products listed below.

Product Name	NDC	Product Description	Refund Period	Refund Amount
Avastin	50242006001	Avastin - 4 ml (100 mg)	2014 Q3	\$0.03 per package
Avastin	50242006001	Avastin - 4 ml (100 mg)	2014 Q4	\$0.01 per package

If any 340B Covered Entity feels they may be eligible for a refund, or has any questions regarding the refund process, Genentech requests those 340B Covered Entities send an email to [contractops@gene.com](mailto:contractops@gene.com) with "Attention: Recalculated 340B Ceiling Prices" in the Subject Line no later than December 31, 2018.